Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, differentiated therapies for infectious diseases. Complementing the product pipeline is a disruptive platform technology to discover rare, potent human monoclonal antibodies from patients. Our scientists and leadership team have a proven track record of innovation and successful drug development of therapeutic candidates from early discovery to commercial implementation. The Companyâs mission is to introduce much needed innovations to infectious disease treatment using an anti-infective product portfolio that includes four (4) clinical stage and two preclinical drug candidates. Our antimicrobial product candidates are highly differentiated from conventional antibiotics in mechanisms of action, and are being developed using clinical study designs that allow for clear demonstration of superiority over standard of care antibiotics. Source
No articles found.
We are a clinical-stage specialty pharmaceutical company dedicated to the developm...
We are a clinical-stage specialty pharmaceutica...
Axovant is accelerating the development of innovative gene therapy products that a...
Axovant is accelerating the development of inno...
Alnylam is leading the translation of RNA interference (RNAi) into a whole new cla...
Alnylam is leading the translation of RNA inter...
Trevena is a biopharmaceutical company focused on the development and commercializ...
Trevena is a biopharmaceutical company focused ...
Avenue Therapeutics, Inc., a Fortress Biotech (NASDAQ: FBIO) Company, is a special...
Avenue Therapeutics, Inc., a Fortress Biotech (...
UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company developing advanc...
UroGen Pharma Ltd. is a clinical-stage biopharm...
At Aethlon Medical, we are a leading developer of immunotherapeutic technologies t...
At Aethlon Medical, we are a leading developer ...
Join the National Investor Network and get the latest information with your interests in mind.